Publications
2021
A systematic cochrane review of corrector therapies (with or without potentiators) for people with cystic fibrosis with class II gene variants (most commonly F508DEL).
Southern, K. W., Murphy, J., Sinha, I. P., & Nevitt, S. J. (2021). A systematic cochrane review of corrector therapies (with or without potentiators) for people with cystic fibrosis with class II gene variants (most commonly F508DEL).. Paediatric respiratory reviews. doi:10.1016/j.prrv.2021.03.001
2012
Mutation-specific therapies that potentiate cystic fibrosis transmembrane conductance regulator (CFTR) function in cystic fibrosis
Sinha, I. P., Southern, K. W., Dwan, K., Echevarria, C., & Schechter, M. (2012). Mutation-specific therapies that potentiate cystic fibrosis transmembrane conductance regulator (CFTR) function in cystic fibrosis. doi:10.1002/14651858.cd009841
2009
Outcomes in Clinical Trials of Inhaled Corticosteroids for Children with Asthma Are Narrowly Focussed on Short Term Disease Activity
Sinha, I. P., Williamson, P. R., & Smyth, R. L. (2009). Outcomes in Clinical Trials of Inhaled Corticosteroids for Children with Asthma Are Narrowly Focussed on Short Term Disease Activity. PLOS ONE, 4(7). doi:10.1371/journal.pone.0006276